NCT07899151

Decision Support for Chemoprevention

RecruitingNAINTERVENTIONAL

Trial Details

Start: 2026-10Est. Completion: 2028-09

Enrollment target: 240 participants

Locations

Columbia University Irving Medical Center, New York, New York, United States

Contact

Research Nurse Navigatorcancerclinicaltrials@cumc.columbia.edu 212-342-5162

Rita Kukafka, DrPH, MArk326@cumc.columbia.edu 212-305-1945

Other microbiome trials you might be interested in

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive CisplatinPhase 3Recruiting

Locally Advanced Hypopharyngeal Squamous Cell CarcinomaLocally Advanced Laryngeal Squamous Cell CarcinomaLocally Advanced Oral Cavity Squamous Cell CarcinomaLocally Advanced Oropharyngeal Squamous Cell Carcinoma

This phase III trial compares cetuximab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation …

Birmingham, United StatesEst. completion Nov 30, 2035

View Trial →

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]Phase 3Recruiting

Non-small Cell Lung CancerNSCLC

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.